beluuga.ai

Overview

Pharmaceutical

K Pharma,Inc.

K Pharma is a Keio University School of Medicine-originated biotech venture focused on two core businesses: iPS drug discovery (iPS創薬) and regenerative medicine, both leveraging induced pluripotent stem cell (iPS cell) technology. The company develops drug candidates for central nervous system diseases—including ALS, Alzheimer's disease, and spinal cord injury—by using disease-specific iPS cell-derived neurons for phenotypic screening and drug repositioning. In parallel, it is advancing allogeneic iPS cell-derived neural cell transplantation therapies targeting spinal cord injury and stroke, with research conducted in collaboration with Keio University and industry partners across the value chain.

Market Cap

¥7.90B

US$50.4M

¥7.18B

US$45.8M

Stock¥680▲+0.59%

US$1 = ¥156.80 (2026-10-23)

LTM EV/EBITDA

—

LTM EV/EBIT

LTM PER

LTM PBR

10.2

Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-16.7%pt

Oct 24, 25 – Oct 23, 26StockTOPIX

MC → EV Bridge

AI Briefing

Generating insights…

Performance & Balance

Net Income 5Y (¥B)

Capital Structure

32%

68%

EquityD/E 2.12xDebt

Liquidity vs Debt 5Y (¥B)▲ Net Cash

CashInv. Sec.Debt

Shareholders

Top 10 hold 76.7%

as of 2026-06-30 · Source: Annual Securities Report

Komei FUKUSHIMA

20.05%

SBI Ventures Two Co., Ltd.

14.85%

Masaya NAKAMURA

10.12%

Hideyuki OKANO

10.03%

Yamato Nittai Bio Venture No. 2 Investment Limited Partnership

9.83%

Kagoshima Value-Up Investment Limited Partnership

5.51%

Alfresa Holdings Corporation

2.71%

Technology Ventures No. 5 Investment Limited Partnership

2.02%

Morgan Stanley MUFG Securities Co., Ltd.

0.90%

Katsunori YOSHIDA

0.68%

Management

8 officers

Komei FUKUSHIMA

Representative Director, President

Apr 1988 Joined Eisai Co., Ltd. Apr 2006 Eisai Research Institute of Boston, Inc. May 2014 Part-time Lecturer, School of Medicine, Keio University Aug 2015 Project Associate Professor (Part-time), School of Medicine, Keio University Nov 2016 Founded the Company; Representative Director, President (current)

1960-07-30

Masato MATSUMOTO

Managing Director, CFO

Nov 2001 Joined PwC Consulting Co., Ltd. (currently IBM Japan, Ltd.) Dec 2005 Joined Mizuho Investors Securities Co., Ltd. (currently Mizuho Securities Co., Ltd.) Feb 2012 Seconded to Mizuho Bank, Ltd. Jul 2013 Seconded to Cross Company, Inc. (currently Stripe International Co., Ltd.) Feb 2016 Joined Stripe International Co., Ltd.; Head of Corporate Planning Office Apr 2016 Director, Stripe International Co., Ltd.; Head of Corporate Planning Office Sep 2021 Joined the Company Oct 2021 Director of the Company Mar 2024 Managing Director of the Company (current)

1975-08-27

Hideyuki OKANO

Director, CSO

Apr 1983 Assistant, Department of Physiology, School of Medicine, Keio University Aug 1985 Assistant, Institute for Protein Research, Osaka University Oct 1989 Studied abroad, School of Medicine, Johns Hopkins University Apr 1992 Assistant, Division of Chemistry, Institute of Medical Science, University of Tokyo Sep 1994 Professor, Department of Molecular Neurobiology, Faculty of Medicine (Basic Medical Sciences), University of Tsukuba Apr 1997 Professor, Department of Neurofunctional Anatomy, School of Medicine, Osaka University Apr 2001 Professor, Department of Physiology, School of Medicine, Keio University Oct 2007 Chairperson, Graduate School of Medicine, Keio University Nov 2008 Visiting Professor, The University of Queensland Apr 2014 Visiting Professor, Hoshi University (current) Apr 2015 Dean, School of Medicine, Keio University Oct 2019 Director of the Company (current) Oct 2021 Visiting Professor, Fujita Health University (current) Jul 2022 Visiting Professor, Massachusetts Institute of Technology (current) Apr 2024 Professor and Director, Center for Regenerative Medicine Research, Keio University (current) Jul 2024 President, International Society for Stem Cell Research (ISSCR) (current)

1959-01-26

Masaya NAKAMURA

Director, CTO

Jan 1998 Visiting Research Fellow, Georgetown University Oct 2000 Assistant, Department of Orthopaedic Surgery, School of Medicine, Keio University Apr 2004 Full-time Lecturer, Department of Orthopaedic Surgery, School of Medicine, Keio University Oct 2007 Part-time Lecturer, Institute of Regenerative Medicine Sciences, Kyoto University Jun 2012 Associate Professor, Department of Orthopaedic Surgery, School of Medicine, Keio University Feb 2015 Professor, Department of Orthopaedic Surgery, School of Medicine, Keio University (current) Oct 2017 Assistant Dean, School of Medicine, Keio University Jul 2019 Managing Director, Japanese Society for Regenerative Medicine (current) Oct 2019 Director of the Company (current) Oct 2021 Vice Dean, School of Medicine, Keio University

1961-07-26

Miho YAMADA

Outside Director

Apr 1989 Joined Mitsubishi Corporation, Osaka Branch Apr 1992 Joined Merrill Lynch Securities, Tokyo Branch (currently BofA Securities Japan Co., Ltd.) Apr 2000 Joined Merrill Lynch Japan Securities (currently Mitsubishi UFJ Morgan Stanley Securities Co., Ltd.) Jul 2009 Director, Le Sank Trust Co., Ltd. Nov 2012 Outside Director, CBS Financial Services Co., Ltd. Jan 2014 Representative Director, CBS Financial Services Co., Ltd. (current) Mar 2025 Outside Director of the Company (current)

1966-09-08

Shunsuke TOYOKAWA

Outside Audit and Supervisory Board Member (Full-time)

Apr 1991 Joined Tsumura & Co. Apr 2010 Head, External Relations and Research Office, Tsumura & Co. Apr 2011 Director and Head, External Relations and Research Office, Tsumura & Co. May 2013 Secretary General, Board of Corporate Auditors, Tsumura & Co. Jun 2017 Secretary General, Audit and Supervisory Committee, Tsumura & Co. Oct 2017 Special Advisor, Internal Audit Office, Tsumura & Co. Apr 2019 Joined Menefit Co., Ltd. Mar 2022 Outside Audit and Supervisory Board Member of the Company (current)

1958-12-05

Yasutaka NISHIDA

Outside Audit and Supervisory Board Member (Part-time)

Apr 2004 Joined Tokyo Legal Affairs Bureau Nov 2005 Joined Shin Nihon & Co. (currently EY Shin Nihon LLC) Oct 2011 Registered as Certified Public Accountant Jan 2012 Head, Yasutaka Nishida Certified Public Accountant Office (current) Oct 2019 Outside Audit and Supervisory Board Member of the Company (current)

1977-11-28

Akiko ISOHATA

Outside Audit and Supervisory Board Member (Part-time)

Oct 2001 Joined Tokyo Hatchobori Law Office; registered as attorney Oct 2011 Partner Attorney, Tokyo Hatchobori Law Office (current) May 2022 Outside Audit and Supervisory Board Member of the Company (current) Jun 2022 Outside Audit and Supervisory Board Member, NEC Networks & System Integration Corporation

1976-02-08

Large Shareholding Reports

Eishi OKANO

2026-04-13

11.05%→10.03%

Annual report (as of 2026-06-30): 10.03%

Disclosures

No disclosures

Primary Source Filings

EDINET

2026-08-13

Semi-Annual Securities Report

Period: Jan 2026 – Dec 2026

K Pharma,Inc.

Try the full product

K Pharma,Inc.

Try the full product

More Japanese companies in Pharmaceutical